Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. (Q30326190)

18 June 2017

1 reference

title

Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. (English)

1 reference

18 June 2017

antibiotic resistance

0 references

1 reference

1 reference

antimicrobial resistance

1 reference

Schentag JJ

1

1 reference

18 June 2017

1 December 1999

1 reference

18 June 2017

Journal of Chemotherapy

1 reference

18 June 2017

11

1 reference

18 June 2017

6

1 reference

18 June 2017

426-439

1 reference

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

18 June 2017

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

The economic potential of dual individualisation methodologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Pharmacodynamic interactions of antibiotics alone and in combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

Gentamicin tissue accumulation and nephrotoxic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1999.11.6.426

10.1179/JOC.1999.11.6.426

21 January 2018

Identifiers

DOI

1 reference

18 June 2017

1 reference

PubMed ID

10678784